. Author manuscript; available in PMC: 2010 Oct 12.

Published in final edited form as: Clin Cancer Res. 2008 Jun 1;14(11):3386–3394. doi: 10.1158/1078-0432.CCR-07-1616

Table 2.

Association between EGFR and PDGFR pathway protein expression and glioma grade

Target	LGG		HGG		Score 3–4: (all gliomas)	Pearson correlation between score 3–4 and HGG (P)	Odds ratio (95% CI)
Target	Score 0–2	Score 3–4	Score 0–2	Score 3–4	Score 3–4: (all gliomas)	Pearson correlation between score 3–4 and HGG (P)	Odds ratio (95% CI)
PDGFRβ	58.3%	41.7%	21.1%	78.9%	50.6%	8.02 (0.005)	5.25 (1.56–17.73)
p-PDGFRα	40.0%	60.0%	14.3%	85.7%	65.0%	4.63 (0.031)	4.00 (1.06–15.08)
EGFR	12.9%	87.1%	20.0%	80.0%	85.4%	0.82 (0.366)	0.55 (0.14–2.06)
p-EGFR	69.4%	30.6%	52.6%	47.4%	34.6%	1.79 (0.180)	2.04 (0.71–5.82)
p-MAPK	29.5%	70.5%	30.0%	70.0%	70.4%	<0.01 (0.967)	0.98 (0.32–2.95)
p-AKT	33.9%	66.1%	15.8%	84.2%	70.4%	2.28 (0.131)	2.73 (0.71–10.44)
p-mTOR	22.6%	77.4%	30.0%	70.0%	76.8%	0.91 (0.340)	0.57 (0.18–1.81)
PTEN^*	32.1%	67.9%	40.0%	60.0%	66.2%	0.33 (0.568)^*	0.71 (0.22–2.30)

For PTEN, in place of score 0 to 2 and 3 to 4 as for the other targets, a score of 0 to 1 was used to represent loss of PTEN expression and a score of 2 was used to represent no loss of PTEN expression compared with that of the vascular endothelium.